vTv Therapeutics Inc.

NasdaqCM:VTVT Stock Report

Market Cap: US$75.3m

vTv Therapeutics Future Growth

Future criteria checks 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de vTv Therapeutics.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth20.8%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Will vTv Therapeutics (NASDAQ:VTVT) Spend Its Cash Wisely?

May 11
Will vTv Therapeutics (NASDAQ:VTVT) Spend Its Cash Wisely?

vTv Therapeutics GAAP EPS of -$0.04

Aug 16

vTv stock soars 18% on $10M equity investment by CinRx Pharma

Jul 25

We Think vTv Therapeutics (NASDAQ:VTVT) Needs To Drive Business Growth Carefully

Aug 17
We Think vTv Therapeutics (NASDAQ:VTVT) Needs To Drive Business Growth Carefully

The Director of vTv Therapeutics Inc. (NASDAQ:VTVT), Richard Nelson, Just Bought A Few More Shares

Mar 03
The Director of vTv Therapeutics Inc. (NASDAQ:VTVT), Richard Nelson, Just Bought A Few More Shares

vTv Therapeutics inks licensing deal for HPP971, shares up 11%

Dec 15

MacAndrews & Forbes buys 625K shares of vTv Therapeutics

Dec 11

vTv Therapeutics raises $47M via stock purchase agreement

Nov 24

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as vTv Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:VTVT - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2023N/A-20-19-19N/A
9/30/20230-22-23-23N/A
6/30/20230-19-27-27N/A
3/31/20230-17-20-20N/A
12/31/20222-19-16-16N/A
9/30/20222-21-16-16N/A
6/30/20225-18-10-10N/A
3/31/20225-16-15-15N/A
12/31/20214-13-19-19N/A
9/30/202110-5-15-15N/A
6/30/20217-5-17-17N/A
3/31/20217-8-18-18N/A
12/31/20206-8-18-18N/A
9/30/20200-15-22-22N/A
6/30/20200-17-22-22N/A
3/31/20202-17-23-23N/A
12/31/20193-18-23-23N/A
9/30/20197-15-23-23N/A
6/30/201911-11-23-23N/A
3/31/201911-12-27-27N/A
12/31/201812-9-27-27N/A
9/30/20188-11-27-27N/A
6/30/20185-14-33-33N/A
3/31/20182-15-36-36N/A
12/31/20170-16-45-45N/A
9/30/20170-16N/A-50N/A
6/30/20170-16N/A-51N/A
3/31/20170-17N/A-50N/A
12/31/20161-16N/A-48N/A
9/30/20161-15N/A-46N/A
6/30/20161-16N/A-43N/A
3/31/20161-22N/A-40N/A
12/31/20151-27N/A-37N/A
9/30/20151-32N/A-35N/A
6/30/20151-34N/A-31N/A
3/31/20152-31N/A-29N/A
12/31/20142-36N/A-31N/A
12/31/20131-48N/A-42N/A

Analyst Future Growth Forecasts

Ingresos vs. tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de VTVT es superior a la tasa de ahorro (2.2%).

Beneficios frente mercado: Datos insuficientes para determinar si se prevé que los beneficios de VTVT crezcan más deprisa que el mercado US

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de VTVT crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de VTVT crezcan más rápido que el mercado de US.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de VTVT crezcan a un ritmo superior a 20% al año.


Earnings per Share Growth Forecasts


Future Return on Equity

Futura rentabilidad financiera (ROE): Datos insuficientes para determinar si la Rentabilidad de los fondos propios de VTVT se prevé elevada dentro de 3 años.


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.